Global Liposome Drug Delivery Market Growth 2024-2030

Publication ID:

LPI01241927

Publication Date:

January 4, 2024

Pages:

123

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Liposome Drug Delivery market size was valued at US$ 3652.8 million in 2023. With growing demand in downstream market, the Liposome Drug Delivery is forecast to a readjusted size of US$ 8742.8 million by 2030 with a CAGR of 13.3% during review period.
The research report highlights the growth potential of the global Liposome Drug Delivery market. Liposome Drug Delivery are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Liposome Drug Delivery. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Liposome Drug Delivery market.
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
Global Liposome Drug Delivery key players include Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, etc. Global top five manufacturers hold a share about 60%. North America is the largest market, with a share about 40%, followed by Europe and Asia-Pacific, both with a share about 30 percent. In terms of product, Liposomal Doxorubicin is the largest segment, with a share about 40%. And in terms of application, the largest application is Cancer & Tumor Therapy, followed by Fungal Infection Therapy, etc.
Key Features:
The report on Liposome Drug Delivery market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Liposome Drug Delivery market. It may include historical data, market segmentation by Type (e.g., Liposomal Doxorubicin, Liposomal Amphoteracin B), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Liposome Drug Delivery market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Liposome Drug Delivery market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Liposome Drug Delivery industry. This include advancements in Liposome Drug Delivery technology, Liposome Drug Delivery new entrants, Liposome Drug Delivery new investment, and other innovations that are shaping the future of Liposome Drug Delivery.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Liposome Drug Delivery market. It includes factors influencing customer ' purchasing decisions, preferences for Liposome Drug Delivery product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Liposome Drug Delivery market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Liposome Drug Delivery market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Liposome Drug Delivery market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Liposome Drug Delivery industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Liposome Drug Delivery market.
Market Segmentation:
Liposome Drug Delivery market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Segmentation by application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gilead Sciences
Pacira
Sun Pharmaceutical
Johnson & Johnson
Luye Pharma
Sigma-Tau
Ipsen (Onivyde)
CSPC
Teva Pharmaceutical
Novartis
Fudan-Zhangjiang
Key Questions Addressed in this Report
What is the 10-year outlook for the global Liposome Drug Delivery market?
What factors are driving Liposome Drug Delivery market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liposome Drug Delivery market opportunities vary by end market size?
How does Liposome Drug Delivery break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Liposome Drug Delivery Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Liposome Drug Delivery by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Liposome Drug Delivery by Country/Region, 2019, 2023 & 2030
2.2 Liposome Drug Delivery Segment by Type
2.2.1 Liposomal Doxorubicin
2.2.2 Liposomal Amphoteracin B
2.2.3 Liposomal Paclitaxel
2.2.4 Others
2.3 Liposome Drug Delivery Sales by Type
2.3.1 Global Liposome Drug Delivery Sales Market Share by Type (2019-2024)
2.3.2 Global Liposome Drug Delivery Revenue and Market Share by Type (2019-2024)
2.3.3 Global Liposome Drug Delivery Sale Price by Type (2019-2024)
2.4 Liposome Drug Delivery Segment by Application
2.4.1 Fungal Infection Therapy
2.4.2 Cancer & Tumor Therapy
2.4.3 Others
2.5 Liposome Drug Delivery Sales by Application
2.5.1 Global Liposome Drug Delivery Sale Market Share by Application (2019-2024)
2.5.2 Global Liposome Drug Delivery Revenue and Market Share by Application (2019-2024)
2.5.3 Global Liposome Drug Delivery Sale Price by Application (2019-2024)
3 Global Liposome Drug Delivery by Company
3.1 Global Liposome Drug Delivery Breakdown Data by Company
3.1.1 Global Liposome Drug Delivery Annual Sales by Company (2019-2024)
3.1.2 Global Liposome Drug Delivery Sales Market Share by Company (2019-2024)
3.2 Global Liposome Drug Delivery Annual Revenue by Company (2019-2024)
3.2.1 Global Liposome Drug Delivery Revenue by Company (2019-2024)
3.2.2 Global Liposome Drug Delivery Revenue Market Share by Company (2019-2024)
3.3 Global Liposome Drug Delivery Sale Price by Company
3.4 Key Manufacturers Liposome Drug Delivery Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Liposome Drug Delivery Product Location Distribution
3.4.2 Players Liposome Drug Delivery Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Liposome Drug Delivery by Geographic Region
4.1 World Historic Liposome Drug Delivery Market Size by Geographic Region (2019-2024)
4.1.1 Global Liposome Drug Delivery Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Liposome Drug Delivery Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Liposome Drug Delivery Market Size by Country/Region (2019-2024)
4.2.1 Global Liposome Drug Delivery Annual Sales by Country/Region (2019-2024)
4.2.2 Global Liposome Drug Delivery Annual Revenue by Country/Region (2019-2024)
4.3 Americas Liposome Drug Delivery Sales Growth
4.4 APAC Liposome Drug Delivery Sales Growth
4.5 Europe Liposome Drug Delivery Sales Growth
4.6 Middle East & Africa Liposome Drug Delivery Sales Growth
5 Americas
5.1 Americas Liposome Drug Delivery Sales by Country
5.1.1 Americas Liposome Drug Delivery Sales by Country (2019-2024)
5.1.2 Americas Liposome Drug Delivery Revenue by Country (2019-2024)
5.2 Americas Liposome Drug Delivery Sales by Type
5.3 Americas Liposome Drug Delivery Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Liposome Drug Delivery Sales by Region
6.1.1 APAC Liposome Drug Delivery Sales by Region (2019-2024)
6.1.2 APAC Liposome Drug Delivery Revenue by Region (2019-2024)
6.2 APAC Liposome Drug Delivery Sales by Type
6.3 APAC Liposome Drug Delivery Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Liposome Drug Delivery by Country
7.1.1 Europe Liposome Drug Delivery Sales by Country (2019-2024)
7.1.2 Europe Liposome Drug Delivery Revenue by Country (2019-2024)
7.2 Europe Liposome Drug Delivery Sales by Type
7.3 Europe Liposome Drug Delivery Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Liposome Drug Delivery by Country
8.1.1 Middle East & Africa Liposome Drug Delivery Sales by Country (2019-2024)
8.1.2 Middle East & Africa Liposome Drug Delivery Revenue by Country (2019-2024)
8.2 Middle East & Africa Liposome Drug Delivery Sales by Type
8.3 Middle East & Africa Liposome Drug Delivery Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Liposome Drug Delivery
10.3 Manufacturing Process Analysis of Liposome Drug Delivery
10.4 Industry Chain Structure of Liposome Drug Delivery
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Liposome Drug Delivery Distributors
11.3 Liposome Drug Delivery Customer
12 World Forecast Review for Liposome Drug Delivery by Geographic Region
12.1 Global Liposome Drug Delivery Market Size Forecast by Region
12.1.1 Global Liposome Drug Delivery Forecast by Region (2025-2030)
12.1.2 Global Liposome Drug Delivery Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Liposome Drug Delivery Forecast by Type
12.7 Global Liposome Drug Delivery Forecast by Application
13 Key Players Analysis
13.1 Gilead Sciences
13.1.1 Gilead Sciences Company Information
13.1.2 Gilead Sciences Liposome Drug Delivery Product Portfolios and Specifications
13.1.3 Gilead Sciences Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Gilead Sciences Main Business Overview
13.1.5 Gilead Sciences Latest Developments
13.2 Pacira
13.2.1 Pacira Company Information
13.2.2 Pacira Liposome Drug Delivery Product Portfolios and Specifications
13.2.3 Pacira Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Pacira Main Business Overview
13.2.5 Pacira Latest Developments
13.3 Sun Pharmaceutical
13.3.1 Sun Pharmaceutical Company Information
13.3.2 Sun Pharmaceutical Liposome Drug Delivery Product Portfolios and Specifications
13.3.3 Sun Pharmaceutical Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Sun Pharmaceutical Main Business Overview
13.3.5 Sun Pharmaceutical Latest Developments
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Information
13.4.2 Johnson & Johnson Liposome Drug Delivery Product Portfolios and Specifications
13.4.3 Johnson & Johnson Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Johnson & Johnson Main Business Overview
13.4.5 Johnson & Johnson Latest Developments
13.5 Luye Pharma
13.5.1 Luye Pharma Company Information
13.5.2 Luye Pharma Liposome Drug Delivery Product Portfolios and Specifications
13.5.3 Luye Pharma Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Luye Pharma Main Business Overview
13.5.5 Luye Pharma Latest Developments
13.6 Sigma-Tau
13.6.1 Sigma-Tau Company Information
13.6.2 Sigma-Tau Liposome Drug Delivery Product Portfolios and Specifications
13.6.3 Sigma-Tau Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Sigma-Tau Main Business Overview
13.6.5 Sigma-Tau Latest Developments
13.7 Ipsen (Onivyde)
13.7.1 Ipsen (Onivyde) Company Information
13.7.2 Ipsen (Onivyde) Liposome Drug Delivery Product Portfolios and Specifications
13.7.3 Ipsen (Onivyde) Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Ipsen (Onivyde) Main Business Overview
13.7.5 Ipsen (Onivyde) Latest Developments
13.8 CSPC
13.8.1 CSPC Company Information
13.8.2 CSPC Liposome Drug Delivery Product Portfolios and Specifications
13.8.3 CSPC Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 CSPC Main Business Overview
13.8.5 CSPC Latest Developments
13.9 Teva Pharmaceutical
13.9.1 Teva Pharmaceutical Company Information
13.9.2 Teva Pharmaceutical Liposome Drug Delivery Product Portfolios and Specifications
13.9.3 Teva Pharmaceutical Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Teva Pharmaceutical Main Business Overview
13.9.5 Teva Pharmaceutical Latest Developments
13.10 Novartis
13.10.1 Novartis Company Information
13.10.2 Novartis Liposome Drug Delivery Product Portfolios and Specifications
13.10.3 Novartis Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Novartis Main Business Overview
13.10.5 Novartis Latest Developments
13.11 Fudan-Zhangjiang
13.11.1 Fudan-Zhangjiang Company Information
13.11.2 Fudan-Zhangjiang Liposome Drug Delivery Product Portfolios and Specifications
13.11.3 Fudan-Zhangjiang Liposome Drug Delivery Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Fudan-Zhangjiang Main Business Overview
13.11.5 Fudan-Zhangjiang Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂